Joseph P Balthasar
Overview
Explore the profile of Joseph P Balthasar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bordeau B, Polli J, Schweser F, Grimm H, Richter W, Balthasar J
Int J Mol Sci
. 2022 Jan;
23(2).
PMID: 35054865
The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor physiology. Improved a priori prediction of mAb pharmacokinetics in...
12.
Bordeau B, Yang Y, Balthasar J
Cancer Res
. 2021 Mar;
81(15):4145-4154.
PMID: 33727230
Poor penetration of mAbs in solid tumors is explained, in part, by the binding site barrier hypothesis. Following extravasation, mAbs rapidly bind cellular antigens, leading to the observation that, at...
13.
Thomas V, Balthasar J
Antibodies (Basel)
. 2019 Dec;
8(4).
PMID: 31817205
Monoclonal antibodies (mAbs) are currently the largest and most dominant class of therapeutic proteins. Inter-individual variability has been observed for several mAbs; however, an understanding of the underlying mechanisms and...
14.
The impact of sialylation linkage-type on the pharmacokinetics of recombinant butyrylcholinesterases
Chung C, Wang Q, Yang S, Chough S, Seo Y, Cipollo J, et al.
Biotechnol Bioeng
. 2019 Sep;
117(1):157-166.
PMID: 31544955
Chinese hamster ovary (CHO) cells typically produce glycoproteins with N-glycans terminating in α-2,3 sialylation. Human cells produce glycoproteins that include α-2,3 and α-2,6 sialic acids. To examine the impact of...
15.
Wang-Lin S, Balthasar J
Antibodies (Basel)
. 2019 Sep;
7(1).
PMID: 31544858
Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and community-acquired infections. Recent advances in monoclonal antibody (mAb) production and engineering have led to renewed interest in the development of antibody-based...
16.
An B, Zhang M, Pu J, Shen S, Qu Y, Chen Y, et al.
Anal Chem
. 2019 Feb;
91(5):3475-3483.
PMID: 30712341
Sensitive and high-throughput measurement of biotherapeutics and biomarkers in plasma and tissues is critical for protein-drug development. Enrichment of target signature peptide (SP) after sample digestion permits sensitive LC-MS-based protein...
17.
Wang-Lin S, Olson R, Beanan J, MacDonald U, Russo T, Balthasar J
J Pharmacol Exp Ther
. 2019 Jan;
368(3):475-489.
PMID: 30606761
has become a pathogen of increasing medical importance because of the emergence of multidrug-resistant strains and the high rate of mortality of infected patients. Promising animal study results have been...
18.
Glassman P, Balthasar J
Drug Metab Pharmacokinet
. 2018 Dec;
34(1):3-13.
PMID: 30522890
Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease...
19.
Li T, Balthasar J
J Pharm Sci
. 2018 Nov;
108(1):714-724.
PMID: 30471293
This work scaled up a previously developed physiologically based pharmacokinetic model to predict the effects of anti-FcRn agents on the disposition of endogenous IgG in human subjects. Simulations were performed...
20.
Li T, Balthasar J
J Pharm Sci
. 2018 Nov;
108(1):701-713.
PMID: 30423340
There is a growing interest in developing inhibitors of the neonatal Fc-receptor, FcRn, for use in the treatment for humoral autoimmune conditions. We have developed a new physiologically based pharmacokinetic...